Urinary Fibroblast Growth Factor-23 and Soluble Alpha-Klotho in Cats with Chronic Kidney Disease.

Urinary FGF23 and Klotho may predict CKD progression in cats and warrant clinical investigation.

This study investigated urinary biomarkers fibroblast growth factor-23 (uFGF23) and soluble alpha-Klotho (uKL) in feline chronic kidney disease (CKD) across disease progression stages. Researchers analyzed samples from 13 healthy cats, 71 CKD cats, and 28 acute decompensated CKD cats using ELISA kits. Key findings demonstrated significantly elevated uFGF23-to-creatinine ratios in late-stage CKD and acute decompensated CKD compared to early CKD and healthy controls (p<0.001). The uKL/uFGF23 ratio showed progressive decline from healthy to late-stage CKD cats. Lower urinary Klotho levels independently predicted CKD progression with hazard ratio of 8.49. These biomarkers reflect dysregulation of phosphorus and mineral metabolism characteristic of CKD-mineral bone disorder. The study suggests uFGF23, uKL, and their ratio may serve as valuable prognostic indicators for disease progression in cats, potentially improving monitoring and therapeutic intervention timing.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.